| metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||
| mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L1 - TMB>10Mb | mNSCLC - L2 - PDL1 negative | |
| Immune checkpoint association | ||||
| durvalumab plus tremelimumab | MYSTIC ... | MYSTIC ... | ARCTIC ... | |
| nivolumab plus ipilimumab | CheckMate 227 ... | CheckMate 227 ... | ||
| nivolumab plus ipilimumab plus SoC | CheckMate 9LA | |||
| pembrolizumab plus ipilimumab | KEYNOTE-598 | |||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
